ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting

  ARIAD Announces Presentations of Preclinical Data at American Association
  for Cancer Research Annual Meeting

Business Wire

CAMBRIDGE, Mass. -- March 20, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of
preclinical data presentations to be made at the American Association for
Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6
through Wednesday, April 10, 2013, in Washington.

Listed below are the details of presentations at AACR that describe ARIAD’s
product candidates. There will be four presentations of data on ARIAD’s
targeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk:

Title: Ponatinib is a highly potent inhibitor of activated variants of RET
found in MTC and NSCLC
Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)
Abstract: #2084
Location: Hall A-C, Poster Section 38

Title: Ponatinib potently inhibits the activity of mutant variants of FGFR
commonly found in endometrial, lung and other cancers
Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster)
Abstract: #2083
Location: Hall A-C, Poster Section 38

Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating
and drug-resistant KIT mutants found in GIST
Date & Time: Tuesday, April 9, 8:00 a.m.–12:00 p.m. (Poster)
Abstract: #3394
Location: Hall A-C, Poster Section 42

Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML
Date & Time: Tuesday, April 9, 9:30–10:00 a.m. (Major symposium)
Presentation: #SY19-04
Location: Salon A-B, East Hall

Title: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant
ALK mutants and oncogenic ROS1 fusions
Date & Time: Wednesday, April 10, 8:00 a.m.–12:00 p.m. (Poster)
Abstract: #5655
Location: Hall A-C, Poster Section 42

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.comor follow ARIAD on
Twitter (@ARIADPharm).

Contact:

ARIAD
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
 
Press spacebar to pause and continue. Press esc to stop.